TG6050
TG6050 an innovative oncolytic virus from the Invir.IO® platform.
TG6050 has been engineered to express into the tumor, human IL-12, a cytokine that triggers a powerful antitumor immune response, and a full length anti-CTLA4 antibody.
Specifically multiply and induce tumor cell lysis (or oncolysis).
Discover how TG6050 works
* requires analytics cookies
Derived from the Invir.IO® platform, our oncolytic viruses infect, specifically multiply and induce tumor cell lysis (or oncolysis).
These viruses also integrate anti-cancer weapons into their genome, enabling them to modulate the tumor microenvironment.
These different mechanisms lead to the destruction of tumor cells and the activation of the immune system, while preserving the patient’s own healthy cells.
Designed to induce a strong immune response against the tumor
Additional ressources
Last publications

- September 10, 2024TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
- August 27, 2024TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
- April 16, 2023TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
Last press releases

- February 6, 2025Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
- January 21, 2025Transgene To Participate in the Biomed Forum Investor Conference
- January 14, 2025Transgene Announces Financial Calendar for 2025
- August 27, 2024Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
- May 10, 2023Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
- April 17, 2023Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
- March 15, 2023Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
- January 6, 2023Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration